Microviable Therapeutics is a biotech company at pre-clinical stage, developing novel biological drugs based on the microbiome to address unmet challenges in infectious diseases, oncology and dermatology. Microviable´s PharmaBiota® platform and proprietary technology has enabled to generate two different product categories, complete microbiota ecosystem products and defined bacterial consortia bas
ed on our large and diverse bacterial strain collection. Microviable´s proprietary technology and derived biological drugs have been protected through patents, trade secrets and trademarks with a growing portfolio of IP. Our lead candidate MVT-201 is a donor-derived complete microbiota ecosystem, with preclinical testing already finalized, that will enter clinical trials in 2024 for a multi-drug resistant infectious disease. Additionally, two other products are currently being developed with preliminary in vitro data available. Microviable has consolidated clinical and research international collaborations to be at the forefront of the microbiome science. Microviable is seeking to stablish collaboration agreements with pharma and biotech companies to license the biological drugs being developed, as well as other potential collaborations to further strength our capabilities in strategic therapeutic areas of interest. Microviable was incorporated in 2016, as a spinoff of the Spanish National Research Council (CSIC), founded by five prestigious research scientist and a business development person with extensive experience in pharmaceutical companies. Microviable has 10 high-qualified employees, it has received the European Seal of Excellence two times, numerous national and regional awards, and the certificate of Innovative SME. www.microviable.com
